The signature might provide five candidate targets (RBMX, FMR1, IGF2BP1, LRPPRC, YTHDC2) associated with specific clinical features, prognosis and improvement in immunotherapy for patients with colorectal cancer. This evidence concerns the gene YTHDC2 and colorectal cancer.